04:34 AM EDT, 08/25/2026 (MT Newswires) -- Bio-Works Technologies (BIOWKS.ST) was selected by a US biotechnology company as a development partner for a new medicine in a deal with a total order value of 2.8 million kronor. The Swedish biotechnology company said Tuesday the collaboration is currently in the development phase. The customer is a global biotechnology company developing medicines and vaccines using advanced mRNA technology.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.